ArticleIranian journal of pathology2026
Optimizing HER2/neu Detection in Equivocal (Score +2) Breast Cancer by Immunohistochemistry (IHC) via Fluorescence in Situ Hybridization (FISH): A Single-Center Experience.
Article in Iranian journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & Objective: Breast cancer is a major global health concern, with HER2/neu overexpression observed in 15%-20% of cases, often indicating a more aggressive disease. It is important to accurately assess HER2 status using IHC and confirm it with FISH testing to guide targeted therapy decisions. The goal of this study was to improve HER2/neu detection in equivocal breast cancer cases, determine the rate of amplification in score +2 cases using FISH, and evaluate the correlation between FISH results and patient demographics such as age. Methods: This retrospective study analyzed 336 archived breast cancer cases with equivocal HER2/neu IHC scores (+2) from 2018 to 2024. IHC initially assessed HER2 expression, and ZytoLight® SPEC ERBB2/CEN 17 probes were used for FISH confirmation. Cases were classified into 5 ASCO-CAP 2023-defined groups based on HER2/CEP17 ratio and HER2 copy number. Final HER2 status guided clinical decision-making regarding eligibility for targeted therapy. Results: The majority of patients were female (91.1%) and aged 40-49 years (29.2%). HER2-negative status was most prevalent (71.1%), while 24.4% were HER2-positive. A significant association was found between gender and HER2 status (P = 0.002), with males showing higher HER2 positivity. A HER2/CEP17 ratio ≥2.0 was strongly associated with HER2 amplification (P = 0.0001). Conclusion:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.